Michał Orleański
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michał Orleański has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Agata Śmiglewska
Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland
2 shared publications - Bogdan Batko
Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Kraków, Poland
2 shared publications - Brygida Kwiatkowska
Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
2 shared publications - Jakub Sowiński
Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland
2 shared publications - Krzysztof Podwójcic
Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland
2 shared publications - Magdalena Krajewska-Włodarczyk
Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland
2 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 212
Psoriatic arthritis incidence and prevalence trajectory in Poland—public-payer, national-level, long-term data
To estimate the actual incidence and prevalence of psoriatic arthritis (PsA) within a 9-year timeframe in Poland. Patients were defined as having PsA if they had at least two visits more than 90 days apart with ICD-10 codes M07.0, M07.1, M07.2, M07.3, or L40.5 and filled at least one reimbursed prescription for peripheral or axial PsA-specific treatments during this period (including methotrexate, sulfasalazine, ciclosporin, leflunomide, biologics, targeted synthetic drugs, or non-steroidal anti-inflammatory drugs). Data was obtained from the nationwide public payer database, considering gender, age, and region of residence. We observed an incidence rate of 1.1 per 100,000 inhabitants in 2021, compared to 13.2 in 2013. Regarding the age of the first diagnosis, the peak incidence rate decreased, with a more pronounced decline in men. The prevalence of PsA rose from 72.5 individuals per 100,000 in 2013 to 95.5 in 2021, representing approximately 0.1% of the total population in Poland, with a significant predominance of women among patients over 55 years of age. The decline in PsA incidence may be influenced by a strict case definition and improved access to treatment. Higher prevalence in older women suggests potential gender-related differences. The lower peak incidence and younger diagnosis age in men raise questions about whether lower PsA prevalence in older males is linked to higher mortality due to longer disease duration and comorbidities. Further research is needed to clarify these findings.
- 2 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 212
Open AccessPsoriatic arthritis incidence and prevalence trajectory in Poland—public-payer, national-level, long-term data
To estimate the actual incidence and prevalence of psoriatic arthritis (PsA) within a 9-year timeframe in Poland. Patients were defined as having PsA if they had at least two visits more than 90 days apart with ICD-10 codes M07.0, M07.1, M07.2, M07.3, or L40.5 and filled at least one reimbursed prescription for peripheral or axial PsA-specific treatments during this period (including methotrexate, sulfasalazine, ciclosporin, leflunomide, biologics, targeted synthetic drugs, or non-steroidal anti-inflammatory drugs). Data was obtained from the nationwide public payer database, considering gender, age, and region of residence. We observed an incidence rate of 1.1 per 100,000 inhabitants in 2021, compared to 13.2 in 2013. Regarding the age of the first diagnosis, the peak incidence rate decreased, with a more pronounced decline in men. The prevalence of PsA rose from 72.5 individuals per 100,000 in 2013 to 95.5 in 2021, representing approximately 0.1% of the total population in Poland, with a significant predominance of women among patients over 55 years of age. The decline in PsA incidence may be influenced by a strict case definition and improved access to treatment. Higher prevalence in older women suggests potential gender-related differences. The lower peak incidence and younger diagnosis age in men raise questions about whether lower PsA prevalence in older males is linked to higher mortality due to longer disease duration and comorbidities. Further research is needed to clarify these findings.
- Open Access
- 27 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1155-1163
Rheumatoid arthritis epidemiology: a nationwide study in Poland
To assess the incidence and prevalence of rheumatoid arthritis (RA) in Poland for the period 2013–2021, total and dependent on gender, age, region and serological status. Information on reported National Health Fund (NHF) health services and reimbursed prescriptions were used, defining an RA patient as a person who had at least two visits in different quarters with ICD-10 code M05 or M06 and at the same time filled at least one reimbursed prescription for a drug whose active substance is methotrexate, sulfasalazine, leflunomide or was treated with biologic disease-modifying anti-rheumatic drugs (bDMRDs) or targeted synthetic DMARDs (tsDMARDs) as part of a drug program financed by the National Health Fund. The nationwide standardised incidence rate of RA in 2021 was 29 persons per 100,000 population (18 per 100,000 population of seropositive vs. 11 per 100,000 population of seronegative RA). The prevalence of RA in Poland in 2021 was 689.0 people per 100,000 population, a total of 0.7% (1.1% in women and 0.3% in men). The incidence of seronegative RA was approximately 38%. The majority of new RA diagnoses were in the sixth and seventh decades of life, irrespective of patients’ gender. The results allow RA to be classified as a disease with a significant social impact. A trend of later onset of RA has been observed, which requires special consideration of the needs of patients over 55 years of age.
- 27 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1155-1163
Open AccessRheumatoid arthritis epidemiology: a nationwide study in Poland
To assess the incidence and prevalence of rheumatoid arthritis (RA) in Poland for the period 2013–2021, total and dependent on gender, age, region and serological status. Information on reported National Health Fund (NHF) health services and reimbursed prescriptions were used, defining an RA patient as a person who had at least two visits in different quarters with ICD-10 code M05 or M06 and at the same time filled at least one reimbursed prescription for a drug whose active substance is methotrexate, sulfasalazine, leflunomide or was treated with biologic disease-modifying anti-rheumatic drugs (bDMRDs) or targeted synthetic DMARDs (tsDMARDs) as part of a drug program financed by the National Health Fund. The nationwide standardised incidence rate of RA in 2021 was 29 persons per 100,000 population (18 per 100,000 population of seropositive vs. 11 per 100,000 population of seronegative RA). The prevalence of RA in Poland in 2021 was 689.0 people per 100,000 population, a total of 0.7% (1.1% in women and 0.3% in men). The incidence of seronegative RA was approximately 38%. The majority of new RA diagnoses were in the sixth and seventh decades of life, irrespective of patients’ gender. The results allow RA to be classified as a disease with a significant social impact. A trend of later onset of RA has been observed, which requires special consideration of the needs of patients over 55 years of age.